Rate of palivizumab administration in accordance with current recommendations among hospitalized children

James A. Moynihan; Tommy Kim; Tammy Young; Paul A. Checchia

doi:10.1016/J.PEDHC.2004.02.006

Rate of palivizumab administration in accordance with current recommendations among hospitalized children

James A. Moynihan, Tommy Kim, Tammy Young, Paul A. Checchia

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction The American Academy of Pediatrics recommends palivizumab prophylaxis for children born premature or with chronic lung disease to reduce the severity of respiratory syncytial virus (RSV) infection. The purpose of the current study is to examine palivizumab administration among children hospitalized with RSV infection. Method This is a retrospective medical record review at a tertiary care children's hospital. The study included children

Original language	American English
Pages (from-to)	224-227
Number of pages	4
Journal	Journal of Pediatric Health Care
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/J.PEDHC.2004.02.006 https://doi.org/10.1016/j.pedhc.2004.02.006
State	Published - Sep 1 2004

ASJC Scopus Subject Areas

Pediatrics, Perinatology, and Child Health

Disciplines

Medicine and Health Sciences
Pediatrics
Critical Care

Access to Document

10.1016/J.PEDHC.2004.02.006License: Unspecified
10.1016/j.pedhc.2004.02.006

OpenUrl availability

Full text

Cite this

@article{2df36d23edb647b8984b2ed096e6249e,

title = "Rate of palivizumab administration in accordance with current recommendations among hospitalized children",

abstract = "Introduction The American Academy of Pediatrics recommends palivizumab prophylaxis for children born premature or with chronic lung disease to reduce the severity of respiratory syncytial virus (RSV) infection. The purpose of the current study is to examine palivizumab administration among children hospitalized with RSV infection. Method This is a retrospective medical record review at a tertiary care children's hospital. The study included children ",

author = "Moynihan, {James A.} and Tommy Kim and Tammy Young and Checchia, {Paul A.}",

note = "Exact barriers to the administration of palivizumab remain unclear. The identification of high-risk children, prevention of RSV by use of palivizumab, and collaboration between hospital and community health care providers will help increase the use of palivizumab and decrease the incidence of RSV.",

year = "2004",

month = sep,

day = "1",

doi = "10.1016/J.PEDHC.2004.02.006",

language = "American English",

volume = "18",

pages = "224--227",

journal = "Journal of Pediatric Health Care",

issn = "0891-5245",

number = "5",

}

TY - JOUR

T1 - Rate of palivizumab administration in accordance with current recommendations among hospitalized children

AU - Moynihan, James A.

AU - Kim, Tommy

AU - Young, Tammy

AU - Checchia, Paul A.

N1 - Exact barriers to the administration of palivizumab remain unclear. The identification of high-risk children, prevention of RSV by use of palivizumab, and collaboration between hospital and community health care providers will help increase the use of palivizumab and decrease the incidence of RSV.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Introduction The American Academy of Pediatrics recommends palivizumab prophylaxis for children born premature or with chronic lung disease to reduce the severity of respiratory syncytial virus (RSV) infection. The purpose of the current study is to examine palivizumab administration among children hospitalized with RSV infection. Method This is a retrospective medical record review at a tertiary care children's hospital. The study included children

AB - Introduction The American Academy of Pediatrics recommends palivizumab prophylaxis for children born premature or with chronic lung disease to reduce the severity of respiratory syncytial virus (RSV) infection. The purpose of the current study is to examine palivizumab administration among children hospitalized with RSV infection. Method This is a retrospective medical record review at a tertiary care children's hospital. The study included children

UR - http://www.ncbi.nlm.nih.gov/pubmed/15337916

UR - https://www.mendeley.com/catalogue/ce0502d3-cb72-323e-8a78-4466885e51ff/

U2 - 10.1016/J.PEDHC.2004.02.006

DO - 10.1016/J.PEDHC.2004.02.006

M3 - Article

C2 - 15337916

SN - 0891-5245

VL - 18

SP - 224

EP - 227

JO - Journal of Pediatric Health Care

JF - Journal of Pediatric Health Care

IS - 5

ER -

Rate of palivizumab administration in accordance with current recommendations among hospitalized children

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this